doi: 10.1200/JOP.000082.
Epub 2010 Aug 6.
American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
Affiliations
- PMID: 21197188
- PMCID: PMC2936467
- DOI: 10.1200/JOP.000082
Item in Clipboard
American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
J Oncol Pract.
2010 Sep.
Abstract
ASCO's technology assessment of the use of aromatase inhibitors in the adjuvant setting was last updated in 2004. ASCO's Update Committee on Aromatase Inhibitors reconvened in May 2009 to update this guideline.
Similar articles
-
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction.J Oncol Pract. 2009 Jul;5(4):196-199. doi: 10.1200/JOP.0948502. J Oncol Pract. 2009. PMID: 29452019 Free PMC article.
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15. J Clin Oncol. 2005. PMID: 15545664 Review.
-
American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer.J Oncol Pract. 2011 Mar;7(2):117-21. doi: 10.1200/JOP.2011.000212. J Oncol Pract. 2011. PMID: 21731520 Free PMC article.
-
Antiemetics: american society of clinical oncology clinical practice guideline update.J Oncol Pract. 2011 Nov;7(6):395-8. doi: 10.1200/JOP.2011.000397. Epub 2011 Oct 21. J Oncol Pract. 2011. PMID: 22379425 Free PMC article.
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.J Clin Oncol. 2002 Aug 1;20(15):3317-27. doi: 10.1200/JCO.2002.06.020. J Clin Oncol. 2002. PMID: 12149306 Review.
Cited by
-
Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model.Pharmaceuticals (Basel). 2022 Dec 17;15(12):1578. doi: 10.3390/ph15121578. Pharmaceuticals (Basel). 2022. PMID: 36559029 Free PMC article.
-
Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.PLoS One. 2014 Oct 21;9(10):e110281. doi: 10.1371/journal.pone.0110281. eCollection 2014. PLoS One. 2014. PMID: 25333877 Free PMC article.
-
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.Int J Environ Res Public Health. 2020 May 23;17(10):3692. doi: 10.3390/ijerph17103692. Int J Environ Res Public Health. 2020. PMID: 32456253 Free PMC article.
-
Sleep and endocrine therapy in breast cancer.Curr Opin Endocr Metab Res. 2021 Jun;18:165-170. doi: 10.1016/j.coemr.2021.03.007. Epub 2021 Apr 8. Curr Opin Endocr Metab Res. 2021. PMID: 34095605 Free PMC article.
-
Cost sharing for breast cancer hormone therapy: How do dual eligible patients' copayment impact adherence.PLoS One. 2021 May 18;16(5):e0250967. doi: 10.1371/journal.pone.0250967. eCollection 2021. PLoS One. 2021. PMID: 34003865 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
